Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
R1507 + sorafenib
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
R1507 + sorafenib is an investigational combination therapy consisting of **R1507**, a fully human IgG1 monoclonal antibody targeting the insulin-like growth factor 1 receptor (IGF-1R), and **sorafenib**, an orally available small molecule multikinase inhibitor. R1507 blocks IGF-1R signaling, which is implicated in tumor growth and survival, while sorafenib inhibits multiple kinases involved in tumor cell proliferation and angiogenesis, including RAF kinases, VEGFR, and PDGFR. The combination has been evaluated for safety and preliminary antitumor activity in patients with various advanced or refractory solid tumors, particularly gastrointestinal stromal tumor (GIST), in early-phase clinical trials[1].
- Brand names
- Nexavar (for sorafenib)
- Other names
- R1507 + sorafenib
02
Targets
VEGFR2 (Vascular endothelial growth factor receptor 2)BRAF (B-Raf proto-oncogene, serine/threonine kinase)PDGFRB (Platelet-derived growth factor receptor beta)KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFR3 (Vascular endothelial growth factor receptor 3)VEGFR-1 (Vascular endothelial growth factor receptor 1)RAF1 (c-Raf-1 (Y340D/Y341D))RET (Rearranged during transfection receptor tyrosine kinase)FLT3 (Fms related receptor tyrosine kinase 3)IGF-1R (Insulin-like growth factor 1 receptor)
Beyond the preview
Go deeper on R1507 + sorafenib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on R1507 + sorafenib.